EGFR NSCLC
Sep 15, 2026
TAGRISSO Delivers Landmark Eight-Year Survival Outcomes in Early-Stage EGFR-Mutated Lung Cancer; Scholar Rock Receives FDA Approval for ISEMBYLD; Pharming’s Joenja Receives FDA Approval as First U.S. Treatment for Children With APDS; AbbVie Reports Positive Phase 3 Results for Atogepant in Menstrual Migraine; Rezera’s Ruvonoflast Delivers Positive Inflammation Results with Favorable Safety in RESOLVE-1
TAGRISSO Demonstrates Eight-Year Landmark Survival Benefit for Patients with Early-Stage EGFR-Mutated Lung Cancer Updated exploratory findings from the Phase III ADAURA trial demonstrated that AstraZeneca’s Tagrisso (osimertinib) continued to provide a sustained and clinically meaningful overall survival (OS) be...
Read More...
Jun 22, 2026
EGFR-Mutant NSCLC: From Targeted Therapy Breakthroughs to the Next Era of Precision Medicine
Summary Non-small cell lung cancer accounts for ~85% of all lung cancer cases, with incidence rising steadily. The EGFR-mutant NSCLC landscape has progressed from 1st/2nd-generation EGFR TKIs (limited by T790M resistance, poor CNS penetration, and toxicity) to more effective 3rd-generation TKIs, with osimert...
Read More...
Jun 05, 2026
The ADC Race in EGFR NSCLC: 5 Contenders Making Big Moves
Summary The EGFR-mutant NSCLC treatment market was valued at USD 6.6 billion in 2025 and is projected to grow at a 7.3% CAGR over the next decade, driven largely by the emergence of targeted biologics and ADCs. The recent approval of Dato-DXd marks a major milestone and is expected to accelerate the adoption...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
